WHWK (Whitehawk Therapeutics) Stock Based Compensation: $10.39 Mil (TTM As of Mar. 2026)


WHWK Whitehawk Therapeutics Inc WHWK
38 GF Score
Price $3.95
GF Value $0.27
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Whitehawk Therapeutics Stock Based Compensation?

Whitehawk Therapeutics WHWK -0.63% 38 Stock Based Compensation is $10.39 Mil as of Mar. 2026. GuruFocus rates WHWK with a GF Score™ of 38/100 and a GF Value™ of $0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Whitehawk Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $2.19 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $10.39 Mil.

Whitehawk Therapeutics Stock Based Compensation Related Terms

Whitehawk Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Whitehawk Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Whitehawk Therapeutics Stock Based Compensation Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 2.11 9.64 11.95 10.84 9.87

Whitehawk Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 3.09 2.72 2.39 2.19
WHWK
38GF Score
Whitehawk Therapeutics Inc WHWK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Whitehawk Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.39 Mil.

What does a Stock Based Compensation of $10.39 Mil mean?
Whitehawk Therapeutics (WHWK) has a Stock Based Compensation of $10.39 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Whitehawk Therapeutics and its competitors.
Is Whitehawk Therapeutics' Stock Based Compensation too high?
Whitehawk Therapeutics' current Stock Based Compensation is $10.39 Mil. Overall, Whitehawk Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' Stock Based Compensation compare to IMUX and TTRX?
Whitehawk Therapeutics' Stock Based Compensation of $10.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Whitehawk Therapeutics and its competitors. Whitehawk Therapeutics's current Stock Based Compensation is $10.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (WHWK) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.27, compared to a current price of $3.95 — trading 1363% above its estimated fair value. The current Stock Based Compensation is $10.39 Mil. Whitehawk Therapeutics' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Whitehawk Therapeutics (WHWK), the current Stock Based Compensation is $10.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Whitehawk Therapeutics (WHWK) Overvalued in 2026?

Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued. The current stock price of $3.95 is trading 1363% above its estimated GF Value™ of $0.27. GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.

Key valuation signals for WHWK:

  • Stock Based Compensation: $10.39 Mil
  • GF Value™: $0.27 vs. price of $3.95 (1363% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the WHWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Whitehawk Therapeutics Business Description

Other Exchanges 3350:Germany
Address 2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
38GF Score

Get the complete analysis for WHWK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.95
Price
$0.27
GF Value